Hypothesis

MOTS-c expression is directly driven by the core circadian transcriptional complex BMAL1/CLOCK acting on mitochondrial DNA, creating a rhythmic peptide signal that synchronizes anabolic Akt activation and catabolic STAT3 suppression in skeletal muscle. Loss of this circadian-MOTS-c axis underlies age‑related muscle atrophy, and restoring timed MOTS-c delivery rescues proteostasis independent of total peptide abundance.

Mechanistic Rationale

1. Mitochondrial transcription responds to nuclear clock factors – BMAL1 and CLOCK have been shown to translocate to mitochondria and bind D‑loop regions, influencing transcription of mtDNA‑encoded genes (e.g., MT‑ND1, MT‑ND2) [1]. The MOTS-c peptide is translated from a small open reading frame within the 12S rRNA region; therefore, circadian occupancy of nearby promoter‑like sequences could modulate its synthesis.
2. Dual signaling architecture – In dexamethasone‑treated human myotubes, MOTS-c uniquely suppresses STAT3 phosphorylation while activating Akt, whereas Humanin only attenuates STAT3 [2]. This bifunctional output matches the opposing phases of the circadian clock: anabolic signaling peaks during the active (day) phase, while catabolic pathways rise during rest (night). A rhythmic MOTS-c pulse could thus temporally gate the Akt/STAT3 balance.
3. Age‑related decoupling – Plasma MOTS-c declines with age [3], and mitochondrial ROS‑driven mTOR/p70S6K activation increases [4]. Both phenotypes are hallmarks of circadian disruption, suggesting that loss of rhythmic MOTS-c removes a temporal brake on mTOR‑mediated catabolism.

Testable Predictions

• Prediction 1: BMAL1/CLOCK occupancy shows a ~24‑hour rhythm at mtDNA regions flanking the MOTS-c ORF, peaking during the subjective day.
• Prediction 2: Endogenous MOTS-c levels in human serum and mouse muscle exhibit a cosine‑shaped oscillation with a trough corresponding to the circadian night.
• Prediction 3: Genetic ablation of Bmal1 in muscle abolishes MOTS-c rhythmicity and shifts Akt/STAT3 signaling toward constitutive STAT3 activation, mimicking dexamethasone atrophy.
• Prediction 4: Exogenous MOTS-c administered at the circadian phase matching the endogenous peak (subjective day) restores myotube fusion and suppresses p‑STAT3 more effectively than the same dose given at the opposite phase.

Experimental Design

1. ChIP‑seq/qPCR – Perform BMAL1 and CLOCK chromatin immunoprecipitation on isolated mitochondria from wild‑type mouse gastrocnemius harvested every 4 h over 24 h. Quantify enrichment at the 12S rRNA/MOTS-c locus.
2. Time‑course peptidomics – Collect human serum and mouse muscle interstitial fluid every 4 h for 48 h using LC‑MS/MS to measure absolute MOTS-c concentrations. Fit cosinor models to assess rhythmicity (amplitude, acrophase, p‑value).
3. Muscle‑specific Bmal1 knockout – Generate HSA‑Cre;Bmal1^fl/fl mice. Compare baseline MOTS-c rhythm, Akt/p‑Akt, and p‑STAT3 levels to littermate controls under sedentary and dexamethasone‑challenged conditions.
4. Timed peptide rescue – Treat dexamethasone‑exposed human myotubes (or Bmal1‑KO mouse myotubes in vitro) with 10 μM MOTS-c either at circadian time CT6 (subjective day) or CT18 (subjective night). Assess myotube fusion index, Akt phosphorylation, STAT3 phosphorylation, and MuRF1 expression after 24 h.

Potential Outcomes

• Supportive: Rhythmic BMAL1/CLOCK binding drives MOTS-c transcription; peptide levels oscillate; loss of Bmal1 flattens the rhythm and shifts signaling toward catabolism; timed MOTS-c administration at the peak phase rescues fusion and Akt activation significantly better than mistimed dosing.
• Refuting: No detectable BMAL1/CLOCK binding at the mtDNA MOTS-c region; MOTS-c levels remain constant across time; Bmal1 deletion does not alter MOTS-c abundance or Akt/STAT3 balance; timed versus untimed MOTS-c yields identical effects.

This framework converts the speculative "anti-aging firewall" concept into a precise, falsifiable mechanism linking circadian genomics, mitochondrial peptide signaling, and muscle aging. Demonstrating circadian gating of MOTS-c would reposition timed peptide delivery as a chronotherapeutic strategy against sarcopenia.